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orsening Heart Failure
ospitalization Epidemic
e Do Not Know How to Prevent
nd We Do Not Know How to Treat!*
aved Butler, MD, MPH, FACC,
ndreas Kalogeropoulos, MD
tlanta, Georgia
ntil the late 1980s, there were no known medical
reatments available to improve survival in patients with
eart failure (HF). Since then, there has been a steady
ncrease in research, resulting in multiple drug- and
evice-related treatment options for these patients. De-
pite these improvements, however, major challenges
oom. The number of cases and deaths attributable to HF
as increased despite advances in treatment and a decline
n other major cardiovascular diseases over the same
nterval. Currently more than 5 million patients in the
.S. have HF, and more than 550,000 are diagnosed
nnually. Heart failure leads to 12 to 15 million office
isits and 6.5 million hospital days, and more than 53,000
atients die of HF as a primary cause annually (1).
arallel trends are seen globally (2).
See page 428
U.S. population demographics are changing. According
o the White House Conference on Aging 2005, the 78
illion “baby boomers” are aging, and as a result, approxi-
ately 1 in 5 Americans are expected to be older than 65
ears by 2050 (3). These trends are projected to have
ignificant impacts on health, health care, and health care
conomics because the use of formal and informal services is
trongly correlated with age. Heart failure is primarily a
isease of the elderly, with an incidence rate of approxi-
ately 10 in 1,000 persons annually after age 65 years;
pproximately 80% of patients hospitalized with HF are
lder than age 65 years (1). The increasing age of the
opulation is expected to worsen the HF epidemic.
Acutely decompensated heart failure (ADHF) resulting
n hospitalization poses specific problems. First, ADHF
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thep
merican College of Cardiology.
From the Cardiology Division, Emory University Hospital, Atlanta, Georgia.arks a fundamental change in the natural history of the
isease progression. Mortality rates in the year following
F hospitalization are higher than in nonhospitalized
atients, and HF hospitalization remains one of the most
mportant risk factors for mortality (4). Second, HF hospi-
alization begets further hospitalization; these patients are
articularly prone to readmission, with recurrent hospital-
zation rates of 50% within 6 months of discharge (1).
hird, HF hospitalization remains the single most impor-
ant driver of the more than $30 billion for cost of care for
hese patients annually (5). Thus, any reduction in HF
ospitalization is likely to result in substantial clinical and
conomic gains.
In light of these facts, the report in this issue of the
ournal by Fang et al. (6) is of alarming importance. The
nvestigators assessed the trends in HF hospitalization using
he National Hospital Discharge Survey data from 1979 to
004. During this time, the number of hospitalizations for
F patients tripled to nearly 4 million in 2004. One-third
f these were primarily HF-related hospitalizations, result-
ng in more than 1 million annual hospitalizations for
ainly HF exacerbation; the rest were admissions with HF
s an additional comorbidity. Not surprisingly, HF hospi-
alization rates increased with age, and more than 80% of
he hospitalizations were among the elderly. What is obvi-
us is that the HF hospitalization epidemic is worsening,
nd at least the short- to intermediate-term future looks
uboptimal. Unless focused measures are taken, the clinical
nd financial burden to society is only going to escalate.
owever, what is not obvious is why, despite improvements
n therapeutic options and outcomes for cardiovascular
iseases in general, do we see these dismal trends for HF
ospitalizations? Root causes for this trend are many; a few
re postulated herein.
. We do not know how to treat ADHF. Despite the
rogress in the treatment of patients with chronic HF, the
esearch effort significantly lags behind for patients with
DHF. Currently there are no clinical trials that have
hown improvement in all-cause mortality for patients with
DHF, and most guidelines are opinion based rather than
vidence based.
. We do not understand the taxonomy of ADHF
yndromes. It is likely that patients who present with
DHF represent a variety of different specific pathophysi-
logic subgroups; currently we treat all patients similarly,
rimarily focusing on diuresis. Understanding the underly-
ng hemodynamic and pathophysiologic subgroups and
ubsequent targeted therapy may represent an improvement
pportunity.
. We do not know how to effectively and safely diurese
atients. Currently, loop diuretics remain the main means
or achieving diuresis. Diuretics are associated with wors-
ning renal function, worsening neurohormonal activation
rofiles, and at least an epidemiologic association with
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nvestigated.
. There is a limited understanding of total body fluid
olume and compartment distribution. Although diuresis
emains the mainstay of therapy, we currently have a limited
nderstanding of the quantitative fluid volume and com-
artment distribution in ADHF. It is possible that some
atients with ADHF (e.g., those with normal ejection
raction and uncontrolled hypertension) may have fluid
edistribution rather than overload. Actively diuresing these
atients may only worsen the primary hemodynamic abnor-
ality (elevated systemic vascular resistance), predisposing
hem to complications. Even in patients who are total body
uid overloaded, the rate of fluid re-equilibration between
xtravascular and intravascular space (plasma refill rate), rate
f diuresis, role of oncotic pressure, and so on may all play
n important role.
. When should we discharge patients? What goals to
chieve? Accuracy of surrogates of volume? Recent data
uggests that many patients with ADHF are discharged
ith 5 lbs or no loss in weight from admission (7). There
re currently no guidelines of when a patient should be
ischarged, and this decision is often based on subjective
mprovement in resting signs and symptoms, which tend to
e insensitive markers of fluid overload. Other surrogates of
olumes are also not ideal either; for example, the pulmo-
ary artery occlusive pressure or the plasma B-type natri-
retic peptide levels may not always represent the overall
olume status. Even if these do represent overall volume
tatus in any given individual, when these surrogate markers
f volume can be safely reduced without complications such
s hypotension or renal failure is poorly understood.
. Fallacy of averages. Most information regarding
DHF is based on cumulative averages of data that do not
dentify and describe the multiple separate ADHF syn-
romes. Hence, generalized statements are made, such as
orsening renal function is associated with worse outcomes
but we do not worry about creatinine rise with angiotensin
I modulation) or that diuretics worsens renal function and
utcomes (and yet diuretics are the most commonly used
rug in ADHF and many patients are safely diuresed
ithout affecting renal function).
. Patient management versus disease management.
ecent data suggest that focused approaches to increase
ompliance with quality measures do not necessarily im-
rove HF outcomes (8). Also, HF patients present with a
uge comorbidity burden that can lead to hospitalization
ither due to comorbidity exacerbation, worsening HF, or
oth (9). Interestingly, Fang et al. (6) show that the increase
n hospitalizations among HF patients with noncardiovas-
ular disease listed as the first diagnosis increased the most
ver time. It is simplistic to believe that focusing only on
F medications and ignoring the comorbidities will result
n significant improvement in outcome. Screening and
reatment of comorbid conditions with a multidisciplinary pntegrated approach is more likely to improve care for these
atients.
. Length of stay and misaligned economic incentives. In
rder to increase the profitability of HF hospitalization,
horter length of stay is a universal goal across all hospital
ystem. Currently the usual length of stay for HF hospital-
zation is about 4 to 5 days in the U.S. The pressures from
he hospital administration to discharge patients quickly in
rder to achieve more net margin and to subsequently fill
he bed with another “more profitable” patient may lead to
remature discharge prior to achieving optimal therapy for
ongestion and of the other comorbid conditions. Coupling
his with a lack of infrastructures to closely follow patients
oon after discharge may lead to increased readmission rates.
. Inadequate post-discharge follow-up. The pressure to
educe length of stay and the possibility of discharge
ithout reaching therapeutic goals underscores the impor-
ance of aggressive and timely outpatient care. A large
roportion of the hospitalization burden for HF represents
arly rehospitalization, suggesting the possibility that out-
atient care is not provided optimally to these patients.
ost-discharge support has been shown to reduce readmis-
ion rate. (10). For example, in a randomized trial compar-
ng usual care with a single home visit after discharge,
nglis et al. (11) showed sustained event-free survival benefit
n the intervention arm among HF patients. The investiga-
ors noted that home visits revealed that 40% of patients
ere found to have undiagnosed early clinical deterioration,
ubjects were in general unable to recognize signs of
otential health crisis, and most exhibited poor self-care
ehaviors or were consuming harmful agents such as non-
teroidal anti-inflammatory drugs. Although the interven-
ion was a “single visit,” all of these issues were addressed
nd patients with signs of clinical deterioration were imme-
iately referred to their physician for remedial actions.
ome visits for all HF patients is a Utopian fantasy; most
atients do not even get a clinic follow-up for several weeks,
f not months, after discharge. Identification of high risk
atients pre-discharge and appropriate timely post-
ischarge follow-up can certainly help reduce the HF
ospitalization crisis.
nyone for heart failure prevention? A rapidly recognized
act in the U.S. health care market is the passive versus
ctive health perception by the society (i.e., equating health
ith the lack of acute sickness or symptoms). Therefore, the
iggest sector of health care research is built around treat-
ent rather than prevention. The overall HF burden and
ubsequently the hospitalization risks will likely not improve
nless HF incidence is decreased. This is unlikely without
educing the burden and treatment of HF risk factors such
s hypertension and diabetes. It is interesting to note that
ang et al. (6) report that the 2 variables that increased
arallel with the increasing HF hospitalizations rates were
he prevalence of hypertension and diabetes. Focused HF
revention efforts are currently rudimentary at best.
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August 5, 2008:435–7 Editorial CommentIn conclusion, we have to accept the following facts. First,
he HF epidemic is here and there is no reason to be
ptimistic that it is not going to get worse. Second, our
cientific knowledge base for ADHF is preliminary. Third,
ultidisciplinary teams including cardiologists, emergency
hysicians, hospitalists, primary care physicians, nurse prac-
itioners, and other specialists must work together to curb this
rowing problem. Fourth, optimal outpatient HF therapy,
oth before hospitalization and especially soon after discharge,
eeds emphasis. Finally, the time for increasing HF prevention
ffort is here. Active understanding of the pathophysiology of
nd improvement in health care delivery models for ADHF
yndromes must be considered an imperative for the na-
ional health care agenda. Fang et al. (6) should be congrat-
lated for bringing to light and quantifying this important
ssue.
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